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The aim of this systematic review is to provide a thorough analysis of published experience regarding outcomes
of LT after controlled DCD compared with donation after brain death (DBD) donors.Background: The interest in donation after cardiocirculatory death (DCD) donors for lung transplantation (LT) has
Methods:Weperformed a literature search in CochraneDatabase of Systematic Reviews, PubMed andWebof Sci-
ence using the items “lung transplantation”AND “donation after circulatory death” onNovember 1, 2018. The full
text of relevant articles was evaluated by two authors independently. Quality assessment was performed using
the NIH protocol for case-control and case series studies. A pooled Odds ratio (OR) andmean differences with in-
verse variance weighting using DerSimonian-Laird random effect models were computed to account for
between-trial variance (τ2).
Results:Of the 508 articles identiﬁedwith our search, 9 regarding controlled donation after cardiac death (cDCD)
were included in the systematic review, including 2973 patients (403 who received graft from DCD and 2570
who had DBD). Both 1-year survival and 2 and 3-grade primary graft dysfunction (PGD)were balanced between
the two cohorts (OR= 1.00 and 1.03 respectively); OR for airway complicationswas 2.07 against cDCD.We also
report an OR= 0.57 for chronic lung allograft dysfunction (CLAD) and an OR= 0.57 for 5-year survival against
cDCD.
Conclusions: Our meta-analysis shows no signiﬁcant difference between recipients after cDCD or DBD regarding
1-year survival, PGD and 1-year freedom from CLAD. Airway complications and long-term survival were both re-
lated with transplantation after cDCD, but these statistical associations need further research.
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The ﬁrst attempt of human lung transplantation (LT), as well as the
ﬁrst LT with long-term survival, was carried out with donation after
cardiocirculatory death (DCD) donors [1,2]. Notwithstanding, trans-
plantations from DCD donors were nearly abandoned in favor of trans-
plantations from brain death donors in the early seventies. Twenty
years later, the interest in DCD donors has been rekindled for two
main reasons: the persistent lung allograft shortage and the hypothesis
according to which lungs from DCD are free from the hemodynamic
perturbations caused by brain death. This last assumption has not
been clearly demonstrated yet. Nevertheless, several preclinical and
clinical studies stated that lung parenchyma survives fairly well after
circulatory arrest [3–6]. In the “modern era”, clinical outcomes follow-
ing DCD LT have proved acceptable; several centers introduced original
protocols to implement such type of donation. The International Society
for Heart and Lung Transplantation (ISHLT) instituted the DCD Registry
in 2011; ten centres from Australia, Europe and North America were in-
vited to participate. The ﬁrst published report from the DCD Registry
concluded that LT using controlled DCD had excellent outcome [7].
The 6th International Conference on Organ Donation, which was held
in Paris in 2014, discussed the reports fromoneuncontrolled and eleven
controlled DCD programs: a list of recommendations was provided [8].
Such recommendations meant to harmonize terminology and basic
concepts that appeared to be fairly inhomogeneous among the consid-
ered twelve DCD programs.
The aim of the present systematic review is to collect published ex-
perience to analyze the outcome of LT from DCD compared with dona-
tion after brain death (DBD) donors.2. Methods
2.1. Search strategy
A literature search in Cochrane Database of Systematic Reviews,
PubMed, and Web of Science was performed by a scientiﬁc librarian
using the items: lung transplantation AND donation after circulatory
death. The search queries are reported in the supplemental material.
Searches were not limited by date or publication status; English lan-
guage was requested. The date of search was November 1, 2018. To
identify additional studies we hand-searched the reference lists of eligi-
ble papers.2.2. Selection criteria
For this review we considered all the original studies, ranging from
case series to randomized trials. The selected papers had to focus on
lung transplantation (including lobe, single-lung, and bilateral trans-
plants); heart-lung transplantation was excluded. We planned to in-
clude studies of comparisons between transplantation from DCD
versus DBD donors.
Titles and abstracts of papers identiﬁed through searching were
screened; the full text of relevant articles was obtained and screened.
Two authors (AR, AP) evaluated each article independently; discrepan-
cies were settled by consensus involving a third author (MN). In case of
overlapping reports from the same center the most recent paper was
considered; data from multi-institutional studies were carefully
checked to avoid duplicates. This study is registered in the PROSPEROInternational Prospective Register of Systematic Reviews, registration
number CRD42018112152.
The primary end-point was 1-year overall survival; secondary end-
points were primary graft dysfunction (PGD), intensive care unit stay,
length of hospital stay, 30-day mortality, airway complications, 1-year
overall survival free from chronic lung allograft dysfunction (CLAD)
and 5-year overall survival.
2.3. Data extraction
The following data were extracted: names of the ﬁrst author, year of
publication, sample size, details of patients' characteristics, PGD rate,
length of stay in intensive care unit and in hospital, 30-day mortality,
airway complication rate, 1-year free from CLAD rate, survival at 1 and
5 years. The corresponding authors of the selected studies were
contacted to obtain unpublished and/or updated data. Data fromeligible
articles as well as the update were collected in a dedicated database.
2.4. Quality assessment
The included studieswere assessed for quality using the protocol for
case-control and case series studies implemented by the National Insti-
tute of Health — National Heart, Lung, and Blood Institute (https://
www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-
risk-reduction/tools/cohort). The tools were independently used by the
two reviewers (AP, AR) (k=0.95). Studies that scored “No” for nomore
than one itemwere assessed as being of good quality; those that scored
“No” for 2 or 3 items were assessed as being of fair quality.
2.5. Statistical analysis
The results of the systematic review were summarized qualitatively
into frequentist meta-analysis. We pooled Odds ratios (ORs) and mean
differences with inverse variance weighting using DerSimonian-Laird
random effect models to account for between-trial variance (τ2) [9].
Heterogeneity among the trials was quantiﬁed by I2-index and
Cochran's Q test [10], considering signiﬁcant heterogeneity when p-
value was b0.10 or I2-index was N50% [11]). A leave-one-out sensitivity
analysis was performed by iteratively removing one study at a time to
conﬁrm that our ﬁndings were not driven by any single study. The
95% conﬁdence intervals (CIs) were based on normal approximation
and Z-score test was performed for assessment of the overall treatment
effect. The 95% conﬁdence intervals for I2 index were calculated accord-
ing to Higgins and Thompson [12]. The 95% prediction intervals for the
treatment effect of a new study are calculated according to Borenstein
[10]. Two-sided p-values were considered statistically signiﬁcant
when p b 0.05. In accordancewith Cochrane guidance,we did not inves-
tigate publication bias because our search considered less than ten stud-
ies for each data comparison. Standard deviations for continuous
outcome variables were calculated according to Hozo, if necessary
[13]. All analyses and graphswere carried out using R software (version
3.2.2) [14].
3. Results
The literature search yielded a total of 508 papers, 429 ofwhichwere
excluded after title matching or abstracts review. Nine of the remaining
79 studies met the inclusion criteria and were included in the system-
atic review. Those 9 papers were eventually considered for the meta-
3A. Palleschi et al. / Transplantation Reviews 34 (2020) 100513analysis including 2973 patients [15–23]. Fig. 1 shows the ﬂow diagram
detailing paper screening and selection. The main characteristics of the
selected study are presented in Table 1.
3.1. Study characteristics
All selected papers reported single center experience except Levvey
who collected the experiences of the Australian centers [18]. Themajor-
ity of the studies were judged “fair” after quality assessment (Fig. 1 in
supplementary materials). In summary, the selected studies included
403 patients who received graft from DCD and 2570 who had DBD. All
the selected analytic retrospective studies were restricted to controlled
DCD according to theMaastricht classiﬁcation; Table 2 shows some spe-
ciﬁc points that characterized the retrieval protocols adopted from the
transplantation centres.
3.2. One-year overall survival
The estimated pooled odds ratio of 1-year overall survival cumula-
tive incidence resulting from 8 studies with a total of 2620 patients
was 1.00 (95% CI = 0.70–1.44; p = 0.973). Prediction lower and
upper limits were 0.43 and 2.30, respectively. The heterogeneity was
low and not signiﬁcant (I2 = 19.2%, 95% CI = 0.0–61.8.7%; p = 0.278)Records sc
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Table 1
Studies selected for review.
Author and
year
Location Time
frame
Study design DCD DBD Recipient
sex (% M)
(DCD/DBD)
Recipient age
(mean)
(DCD/DBD)
BMI
(DCD/DBD)
Bilateral
LT (%)
(DCD/DBD)
Q. A. Update
Puri, [15] St. Louis, MO 2003–2008 Analytic retrospective
cohort, single center
11 282 N.R. 54/48 21.6/22.6 100/95.4 Fair No
De oliveira, [16] Madison, WI 1993–2009 Analytic retrospective
cohort, single center
18 406 61/63 47/50 23/24 50.0/36.0 Fair No
Van de wauwer, [17] Groningen, Nl 2005–2009 Analytic retrospective
cohort, single center
35 77 34/51 54/53 N.R. 85.7/71.4 Fair No
Levvey, [18] Australia 2006–2011 Analytic retrospective
cohort, multi-center
133 905 56/50 43/46 N.R. 95.8/86.4 Good Yes
Sabashnikov, [19] Hareﬁeld, UK 2007–2013 Analytic retrospective
cohort, propensity score
matching, single center
60 120 55/43 43/41 21.1/22.3 97.9/99.0 Good No
Ruttens, [20] Leuven, Be 2007–2013 Analytic retrospective
cohort, single center
59 331 62/48 51/50 N.R. 98/92 Fair No
Costa, [21] New York, NY 2007–2016 Analytic retrospective
cohort, single center
46 237 43/58 58/57 N.R. 50/47 Fair Yes
Inci, [22] Zurich, Ch 2012–2017 Analytic retrospective
cohort, single center
21 151 57/55 49/50 21/21 100/97 Fair No
Barbero, [23] Cambridge, UK 2009–2015 Analytic retrospective
cohort, single center
23 163 51/59 58/50 24/24 70/82 Fair No
DCD: patients transplanted with donation after cardio-circulatory death; DBD: patients transplanted with donation after brain death; Q.A.: quality assessment according the National
Institute of Health. N.R.: not reported.
4 A. Palleschi et al. / Transplantation Reviews 34 (2020) 100513Six papers reported the frequency of the airway complications: the
prevalence ranged from 4.7 to 27.7 in DCD cohorts versus 1.3 to 18.8
in DBD cohorts. The estimated pooled odds ratio of airway complica-
tions resulting from 4 studies with a total of 962 patients was 2.07
(95% CI = 1.09–3.94; p = 0.026). Prediction lower and upper limits
were 0.51 and 8.47, respectively. The heterogeneity was I2 = 0.0%
(Fig. 4 in the supplementary material). The sensitivity analysis shows
that by omitting the De Olivera's study the overall effect test becomes
no longer signiﬁcant (0.147 vs 0.026) (Fig. 4 in the supplementary
material).
Data on 1-year survival rate free fromCLADwere available in 6 stud-
ies; the estimated pooled odds ratio resulting from 5 studieswith a total
of 1002 patients was 0.57 (95% CI = 0.19–1.72; p = 0.321). Prediction
lower and upper limits were 0.01 and 23.63, respectively. The heteroge-
neity wasmoderate but not signiﬁcant, I2 = 34.1% (Fig. 5 in the supple-
mentarymaterial). The sensitivity analysis showed that by omitting Van
De Wauwer's study the overall effect test becomes statistically signiﬁ-
cant (0.321 vs 0.041) and odds ratio decreases from 0.57 to 0.38 with
upper limit of 95% conﬁdence interval equal to 0.96 (Fig. 5 in the supple-
mentary material).
Five papers reported the 5-year survival rate of 1631 patients; the
estimated pooled odds ratio was 0.57 (95% CI = 0.43–0.76; p b 0.001).Table 2
Main characteristics of the controlled DCD protocols.
Author and year “Hands off” time (min) Interval 2 (min) Interval 4 (
Puri, [15] 5 n.a. n.a.
De Oliveira, [16] 5 n.a. n.a.
Van De Wauwer, [17] 5 17 n.a.
Levvey, [18] 2–5 18 21
Sabashnikov, [19] 5 n.a. n.a.
Ruttens, [20] 5 n.a. n.a.
Costa, [21] 5 23 14
Inci, [22] 10 17 37
Barbero, [23] 5 14 34
Intervals for cDCD donors recommended by ISHLT DCDWorking Group: Interval 2: from withd
blood pressure b 50 mmHg to cold ﬂush; Interval 3: from withdrawal of life-sustaining therap
a Absence of precise indication.
b “Cold ischemic time”.
c From cold ﬂush to the reperfusion.
d From cardiac arrest to ﬁrst lung reperfusion.The prediction lower and upper limits were 0.36 and 0.91, respectively.
The heterogeneity was low, I2 = 0.0% (Fig. 2). The sensitivity analysis
documented the robustness of the results (Fig. 6 in the supplementary
material).
4. Discussion
The number of papers published on DCD has been increasing as a
result of a growing interest in this peculiar type of donation. Bearing
in mind that randomized controlled trials are almost impossible to
carry out in this context, some reviews were published with the aim
of getting some scientiﬁc evidence on lung transplantation. In 2008,
Oto published a review that collected 8 papers (39 patients); the author
concluded that LT after controlled DCD had adequate early clinical out-
comes, whereas the use of uncontrolled DCD seemed to be related to
high incidence of PGD [24]. Wigﬁeld published in 2014 a narrative
review conﬁrming the good early outcome of LT after DCD; this paper
underlined the differences among protocols, namely in the use of
ex-vivo lung perfusion (EVLP) [25]. A systematic review and meta-
analysis was published by Krutsinger and collaborators in 2015; this
well conducted study collected 11 articles, 6 of which entered the
meta-analysis (DCD cohort: 271 recipients; DBD cohort: 2369) [26].min) Interval 3 (min) Lung reconditioning Ischemic time (min)
n.a. no 266a
30 no 392b
29 no 458c
35 no 254d
n.a. occasional (EVLP or OCS) 346a
21 no 314a
32 no n.a.
42 Occasional (EVLP) n.a.
n.a. no n.a.
rawal of life-sustaining therapies or euthanasia to cardiac arrest; Interval 4: from systolic
ies or euthanasia to cold ﬂush.
Fig.2. A) Forest plot of pooled analysis for 1-year survival after lung transplantation. B) Forest plot of pooled analysis for 5-year survival.
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rate between patients who received graft from DCD or DBD; PGD and
acute cellular rejection rates were also similar between the two
patients' cohorts [26]. The Erasmus review formulated a number of
recommendations analyzing 12 DCD programs [8]. The ﬁrst 7 general
recommendations have, for the most part, a low degree of evidence;
all remaining 6 recommendations addressing the uncontrolled DCD
were given evidence grade “D”. In this context it is evident that great ef-
forts will be necessary to bring DCD in the area of evidence based
medicine.
The present review gathered nine analytic retrospective studies, al-
most doubling the DCD cohort analyzed by Krustinger. Originally, we
were not going to restrict our research on the basis of DCD Maastricht
category, but the studies with control arms only included category III
donors; therefore, this review is focused on controlled DCDs. The recip-
ient selectionswere inhomogeneous: Puri consciously attempted to use
the DCD graft for recipients considered to be at baseline risk for periop-
erative complications [15]; on the contrary, De Oliveira's recipient co-
hort nearly always included the sickest listed patients [16]. This
apparently dichotomous behavior probably reﬂects the overall impres-
sion that lungs from DCD are somehow inferior in quality to those ob-
tained from DBD. Recent studies openly stated that recipient selection
according to donor type was avoided; or, at least, the lack of selection
can be probably inferred from the analysis of the characteristics of the
cohorts [17–23]. Donor selection criteria were not clearly stated in
some papers [17,20,21,23], whereas others accepted donors with “ex-
tended criteria” such as smoking history of N 20 pack/years, intensive
care unit stay N 5 days, PaO2/FiO2 b 400 mmHg, and abnormal chest
X-ray [18,19,22]. Puri did not accept DCD donors deﬁned as “marginal”
[15]. It is obvious that this inhomogeneity in recipient as well as donor
selection, together with the typical distortions of observational studies,
created some confusion and enrolment bias were possible.The “hands off” time was 5 minutes for almost all centers except for
Zurich (10 minutes) and some Australian centers (2 minutes) [18,22].
"Hands off" times of this entity are not considered capable of signiﬁ-
cantly impacting the results, while precise limits of the agonic time
were established through different protocols. The Groningen protocol
[17] limited the agonic time to 60 minutes, while Australian protocols
ranged from 60 to 90 minutes [18]; the two British protocols were
more liberal, extending the acceptability up to 2 hours following with-
drawal of life support or up to 1 hour following onset of warm ischemic
period [19,23]. When reported, the mean duration of interval 2 (from
withdrawal of life-sustaining therapies to cardiac arrest) ranged from
14 to 23 minutes; these time intervals were safely below the stated
limits (Table 2). How extensive the warm ischemic time may be to
prove acceptable is yet to be determined. We had a favorable 1-year
outcome in recipients of lungs procured from DCD donors with ex-
tended warm ischemic time: average 157 minutes (range 118–179)
(personal communication at the 8th International Meeting on Trans-
plantation from DCD, Milan on September 13-14, 2018).
The majority of the procurement protocols included rapid
sternotomy and pulmonary arterial cannulation for the delivery of the
preservation solution [16–20,22]; some authors preferred topical
cooling immediately after sternotomy [15,21,23]. Both procedures pres-
ent advantages and drawbacks; topical cooling guarantees a rapid
downturn of cellular metabolism (even though the lung parenchyma
has the property to decouple ischemia from hypoxia and all protocols
provide for the maintenance of the ventilation during the procure-
ment); on the other hand, avoiding the ﬂooding of the pleural space al-
lows an accurate inspection of the parenchyma.
Most of the centres did not evaluate the lungs with EVLP after pro-
curement. This fact is easily explained, as a proper functional evaluation
was achievable shortly before the withdrawal of life support. Neverthe-
less, EVLP is an appropriate tool for the evaluation of graft function
6 A. Palleschi et al. / Transplantation Reviews 34 (2020) 100513when extended criteria donors are considered. Moreover, the use of
EVLP is advised in case of interval between withdrawal of life support
therapy and cardiac arrest greater than 60 minutes or if pulmonary
edema, poor compliance or high-risk history are likely present [27].
The odds ratio for 1-year overall survival (primary end-point of cur-
rent meta-analysis) was perfectly balanced between the two cohorts,
even though a “conservative” random model was used. These ﬁndings
strengthen the result obtained by Krustinger and collaborators [26],
considering that 3 new analytic retrospective cohort studies were pub-
lished along with 2 adjourned papers. Our result was also reinforced
with the leave-one-out sensitivity analysis that evaluated the ambiguity
in the output distributed to each selected study considered as source of
uncertainty [28]. We think that it is now possible to state with reason-
able certainty that controlled DCD guarantees 1-year overall survival
after LT not less than DBD.
Our pooled analysis shows that there is no difference in grade 2-3
PGD rates between recipients of DCD and DBD. Despite this, the result
was straightened by heterogeneity and sensitivity tests; it is important
to underline that PGD data were reported in different ways and, as a
consequence, this result must be taken with caution. Our result, as
well as Krustinger's, supported the hypothesis that Maastricht class III
donors offer lung grafts without the negative impact caused by brain
death. Such hypothesis has been well demonstrated in animal studies
where catecholamine discharge, inﬂammatory response and higher im-
munogenicity caused by brain death could result in acute lung injury.
The ischemia reperfusion injury affects DBD as well as DCD organs but
the warm ischemic time after the cardiac arrest can worsen inﬂamma-
tion and vascular leakage. The early resumption of ventilation, the pre-
conditioning effect and the possibility of using EVLP seem to mitigate
the noxae for the lungs during the DCD process. Despite the need to
accumulate further (possibly prospective) clinical studies, it is now
becoming increasingly evident that controlled DCD guarantees a
short-term outcome which overlaps at least with that obtained from
LT with DBD.
One-year freedom from CLAD was never tested in a meta-analysis;
our results documented balanced odds ratio for this parameter. The re-
sultmust be takenwith caution considering that cohort size andhetero-
geneity tests are on the edge of acceptability. On the other hand, it is
well known that “autonomic storm” takes place during brain death;
after initial increase in the parasympathetic tone, an earlymassive sym-
pathetic outﬂow is produced. Organs, which are exposed to intense
sympathetic stimulation, face the release of adhesion molecules, cyto-
kines, chemokines as well as overexpression of histocompatibility anti-
gens [29]. Theoretically, the absence of this over-expression could help
to reduce the rate of CLAD and improve medium-term survival in LT
from controlled DCD.
A debated point in DCD is the possibility of airway complications as a
consequence of main bronchi hypoperfusion during low-ﬂow state. Our
pooled analysis fuels this concern, stating that the odds ratio for airway
complications was 2 against LT with DCD. This result deserves few con-
siderations: there is institutional variability in the deﬁnition of airway
complications and the cohorts were of relatively small size, despite het-
erogeneity being the lowest possible. In addition, such negative result
for DCD disappeared if one study was omitted in the sensitivity analysis
[16]. Considering how experimental studies pointed out the impaired
healing of the bronchial anastomosis in LT from DCD, this item will re-
quire special attention in future reports; increasing the effort for homo-
geneous deﬁnitions and careful analysis of confounding factors will also
prove necessary [30].
Lastly, long-term survival tested with pooled analysis was signif-
icantly in favor of LT with DBD. The interpretation of this result is
problematic; 5-year survival could be lower in controlled DCD recip-
ients as a consequence of bias in the lungs allocation: some authors
preferred DCD graft in patients with severe clinical condition (pa-
tients judged too compromised to wait for DBD graft); other authors
selected patients with low priority who have to wait a long time for aDBD graft. It is possible that long-term survival may be more affected
by the pre-existing conditions of the recipient and his/her manage-
ment than by the type of donor [31]. In any case, the heterogeneity
of the 5 included studies is extremely low; therefore, a consistent
number of new trials is needed to alter the disadvantage of the DCD
recipients.
Limitations of this study include the retrospective nature of the se-
lected papers. The cohorts have been matched with propensity score
only in one article; the number of patients was small, with only 392 re-
cipients in controlled DCD cohort. Allocation bias between the two co-
horts was highly probable, namely with regard to recipient selection.
Pooled analysis was inconclusive for ICU and hospital stay because of
extreme heterogeneity. Lastly, 1-year follow-up is a relatively short
timeframe when referred to CLAD; in addition, old papers reported
bronchiolitis obliterans syndrome rather than CLAD.
In conclusion, thismeta-analysis indicates that there is no signiﬁcant
difference in 1-year overall survival, PGD and 1-year freedom from
CLAD between recipients of controlled DCD or DBD lungs. Conversely,
a warning is mandatory for airway complications and 5-year survival,
despite the effective responsibility of the donor type beingquestionable.
In this context, it remains vital for centers to continue publishing their
experience on DCD to achieve high quality evidences.
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